| 000 | 01756 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515135946.0 | ||
| 264 | 0 | _c20090225 | |
| 008 | 200902s 0 0 eng d | ||
| 022 | _a1462-0332 | ||
| 024 | 7 |
_a10.1093/rheumatology/ken369 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSabnani, I | |
| 245 | 0 | 0 |
_aA novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. _h[electronic resource] |
| 260 |
_bRheumatology (Oxford, England) _cJan 2009 |
||
| 300 |
_a49-52 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 |
_aCyclophosphamide _xadverse effects |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadverse effects |
| 650 | 0 | 4 |
_aLung Diseases, Interstitial _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPiperazines _xadverse effects |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadverse effects |
| 650 | 0 | 4 |
_aProtein-Tyrosine Kinases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aPyrimidines _xadverse effects |
| 650 | 0 | 4 |
_aScleroderma, Systemic _xcomplications |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aZucker, M J | |
| 700 | 1 | _aRosenstein, E D | |
| 700 | 1 | _aBaran, D A | |
| 700 | 1 | _aArroyo, L H | |
| 700 | 1 | _aTsang, P | |
| 700 | 1 | _aZubair, M | |
| 700 | 1 | _aRivera, V | |
| 773 | 0 |
_tRheumatology (Oxford, England) _gvol. 48 _gno. 1 _gp. 49-52 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/rheumatology/ken369 _zAvailable from publisher's website |
| 999 |
_c18282381 _d18282381 |
||